|Boston Strategics Corp. Initiates a Phase 1 Clinical Trial of the Anti-cancer Agent "FF-10501"|
|By Staff and Wire Reports|
|Friday, 29 August 2014 19:14|
Boston Strategics Corporation (BSC), a primary global strategic drug development provider for FUJIFILM Pharmaceuticals U.S.A., Inc. (FPHU), has begun a Phase 1 clinical trial of FUJIFILM’s anti-cancer agent FF-10501 in the United States in patients with advanced hematologic malignancies, such as relapsed or refractory high-risk myelodysplastic syndromes (MDS). The trial is carried out at the University of Texas MD Anderson Cancer Center (MD Anderson) with Guillermo Garcia-Manero, M.D., Professor, as the Principal Investigator. Prof. Garcia-Manero is a world-renowned expert in advanced hematologic malignancies, especially MDS.
MDS is a type of hematologic malignancy, in which the disorder of blood-forming "hematopoietic stem cells" causes inefficient production of blood cells triggering cytopenia. It is also a refractory disease for some patients with poor prognosis, progressing to acute myeloid leukemia. The U.S. incidence of MDS is 60,000 cases per year, most of them in the senior age group. FF-10501 is expected to inhibit the growth of hematological cancer cells and promote their differentiation to normally functioning cells.
MD Anderson is one of the world's top general cancer centers with over 10,000 patients enrolled in therapeutic clinical trials each year and approximately 20,000 employees. BSC is able to utilize the world's top-level clinical testing functions available at the MD Anderson under a Strategic Alliance Agreement to carry out Phase 1 and early Phase 2 clinical trials to gain preliminary safety information and clinical activity in cancer patients. “We are very excited to be collaborating with FPHU and BSC on this important clinical trial in patients with advanced hematologic malignancies,” said Prof. Guillermo Garcia-Manero. “This drug will provide another alternative for patients who have failed conventional chemotherapeutic approaches, and we are pleased to be furthering this research at our institution.”
This clinical trial is the first example of a BSC and FPHU collaboration, whereby BSC optimizes and executes the global strategy of FPHU Oncology drug development programs. Utilizing Boston Strategics’ internal oncology development expertise and its ability to leverage the “True” Open Innovation™ network to collaborate with the best resources around the world, BSC will be able to deliver to FPHU more efficient and superior outcomes to cancer patients worldwide.
“This is a important milestone in BSC and FPHU partnership to develop a new pharmaceutical R&D platform for FPHU, which looks for an innovative and efficient way for global development of FUJIFILM’s unique oncology pipeline“, says Eita Kitayama, President of Boston Strategics. “Both companies are fully committed to deliver breakthrough therapies using innovative approaches to achieve industry benchmark-beating timelines, quality, and financial investments for important novel anti-cancer agents.”
22nd Century Group, Inc. (NYSE MKT:XXII) announced today that NASCO Products, LLC, a federally licensed tobacco product manufacturer and participating member of the tobacco Master Settlement Agreement (MSA), entered into a multi-year manufacturing agreement with Smoker Friendly International to produce the Smoker Friendly private label cigarette brand.
Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, will visit the NASDAQ MarketSite in Times Square.
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced the appointment of Mr. Iain Ross to the Company's Board of Directors, Mr. Ross brings over 30 years of biopharmaceutical industry experience to Amarantus across executive management, investment and directorship roles.
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded a contract modification for an additional $2.4 million to BioCryst to conduct a dose ranging efficacy study of an intramuscular formulation of BCX4430 in non-human primates as a treatment for Ebola virus disease.
BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases, today announced financial results for the second quarter ended June 30, 2014.
BIOLASE, Inc. (BIOL), the world’s leading dental laser manufacturer and distributor, announced today that it held its Annual Meeting of Stockholders on Wednesday, August 27, at the Company's corporate headquarters in Irvine, CA, as scheduled.
CONMED Corporation (Nasdaq:CNMD) today announced that Institutional Shareholder Services (ISS) and Egan-Jones Proxy Services ("Egan-Jones"), leading independent proxy advisory firms, have recommended that CONMED shareholders vote "FOR" ALL of CONMED's director nominees on the GOLD proxy card at the Company's September 10, 2014 Annual Meeting of Shareholders.
Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, will be filing a Form N-CSR today disclosing its schedule of portfolio holdings as of June 30, 2014.
Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, announced today that Ekso Bionics will be demonstrating their technology at the Academy of Spinal Cord Injury Professionals 2014 Educational Conference and Expo August 31st thru September 3rd at Hyatt Regency at the Arch, St. Louis Missouri.
Invacare Corporation (NYSE: IVC) announced today that it has completed the sale of Altimate Medical, Inc. (Altimate), its domestic manufacturer of stationary standing assistive devices for use in patient rehabilitation, to Rockwood Equity Partners for approximately $23,000,000 in cash, subject to a $1,000,000 escrow arrangement and further subject to certain post-closing adjustments.
MedAssets (Nasdaq:MDAS) today announced that it will participate in two investment conferences during the first week of September.
Senesco Technologies, Inc. (OTCQB:SNTI) today announced the closing of enrollment in its ongoing Phase 1b/2a open-label, multiple-dose, dose-escalation clinical trial of SNS01-T, a first-in-class modulator of eukaryotic translation initiation factor 5A (eIF5A), in patients with relapsed or refractory multiple myeloma, plasma cell leukemia or B cell lymphoma.
Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) reports that, in view of the unusual market trading activity in the Company's stock, the Investment Industry Regulatory Organization of Canada (IIROC) has contacted the Company in accordance with its usual market surveillance practice.
Unilife Corp (UNIS; ASX: UNS) announced today that it intends to release its financial results for the fiscal 2014 fourth quarter and year ended June 30, 2014 after market trading ends on Tuesday, September 9, 2014.